

# Kohei Kaku

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7934659/kohei-kaku-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196  
papers

2,675  
citations

28  
h-index

44  
g-index

212  
ext. papers

3,244  
ext. citations

4.6  
avg, IF

5.32  
L-index

| #   | Paper   | IF  | Citations |
|-----|---|-----|-----------|
| 196 | Formation of large abscess tumor including gallstone in ileum during therapy for hyperosmolar hyperglycemic syndrome: a case report.. <i>Diabetology International</i> , <b>2022</b> , 13, 320-324  | 2.3 |           |
| 195 | Case Report: Onset of Type 1 Diabetes Mellitus in a Patient With Ulcerative Colitis and Sjogren's Syndrome Under Euthyroid Hashimoto's Thyroiditis.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 836102   | 5.7 | 0         |
| 194 | The efficacy and safety of once-weekly semaglutide in Japanese subjects with type 2 diabetes by baseline age and body mass index.. <i>Journal of Diabetes Investigation</i> , <b>2022</b> ,   | 3.9 | 2         |
| 193 | Acute respiratory distress syndrome triggered by marked cytokine storm in a subject with diabetic ketoacidosis: A case report.. <i>Medicine (United States)</i> , <b>2022</b> , 101, e29119   | 1.8 |           |
| 192 | Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 843480  | 8.4 | 1         |
| 191 | Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 871660   | 5.7 | 0         |
| 190 | Serious diabetic ketoacidosis induced by insulin allergy and anti-insulin antibody in a subject with type 2 diabetes mellitus.. <i>Journal of Diabetes Investigation</i> , <b>2022</b> ,  | 3.9 | 0         |
| 189 | Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> ,                                       | 6.7 | 7         |
| 188 | Case Report: Markedly Long-Term Preservation of Pancreatic $\beta$ Cell Function in a Subject With Elderly Onset of Type 1 Diabetes Mellitus Showing High-Titer Autoimmune Antibodies for Over 4 Years.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 752423  | 8.4 | 1         |
| 187 | Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 722586                                    | 5.7 | 1         |
| 186 | Pyogenic psoas abscess on the dorsal side, and bacterial meningitis and spinal epidural abscess on the ventral side, both of which were induced by spontaneous discitis in a patient with diabetes mellitus: A case report. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 1301-1305                | 3.9 | 1         |
| 185 | New prospects for incretin-related drugs in the treatment of type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 1141-1143  | 3.9 | 2         |
| 184 | Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3 | 12        |
| 183 | Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 1610-1618 | 3.9 | 2         |
| 182 | Case Report: A Case of Pituitary Adenoma Producing Growth Hormone and Thyroid-Stimulating Hormone Simultaneously. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 659076  | 5.7 | 0         |
| 181 | Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3 | 2         |
| 180 | Effects of sedentary behavior and daily walking steps on body mass index and body composition: Prospective observational study using outpatient clinical data of Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 1732-1738                                   | 3.9 | 0         |

|     |  |     |   |
|-----|--|-----|---|
| 179 | Case Report: Emphysematous Cystitis and Pyelonephritis Induced by Uterine Prolapse in a Subject With Untreated Diabetes Mellitus. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 658682   | 4.9 | 1 |
| 178 | Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 707-720   | 4.1 | 2 |
| 177 | Clinical Characteristics of Withdrawal of Basal Insulin Therapy Among Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 1849-1860   | 3.6 | 0 |
| 176 | Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 1805-1815   | 3.9 | 0 |
| 175 | Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1660-1665  | 6.7 | 3 |
| 174 | Case Report: Malignant Pheochromocytoma Without Hypertension Accompanied by Increment of Serum VEGF Level and Catecholamine Cardiomyopathy. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 688536   | 5.7 | 2 |
| 173 | Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2099-2108  | 6.7 | 3 |
| 172 | A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time. <i>BMC Endocrine Disorders</i> , <b>2021</b> , 21, 115   | 3.3 | 1 |
| 171 | Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 184-199                    | 3.9 | 2 |
| 170 | Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better. <i>Scientific Reports</i> , <b>2021</b> , 11, 1425  | 4.9 | 6 |
| 169 | Persistent Hypoglycemia Induced by Long-acting Insulin Degludec. <i>Internal Medicine</i> , <b>2021</b> ,  | 1.1 | 1 |
| 168 | A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1342-1350   | 6.7 | 1 |
| 167 | A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1242-1251                             | 6.7 | 3 |
| 166 | Favorable Effects of GLP-1 Receptor Agonist against Pancreatic $\beta$ Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better" in Therapy with Incretin-Based Medicine. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,                    | 6.3 | 1 |
| 165 | Concurrence of overt Cushing's syndrome and primary aldosteronism accompanied by aldosterone-producing cell cluster in adjacent adrenal cortex: case report. <i>BMC Endocrine Disorders</i> , <b>2021</b> , 21, 163  | 3.3 | 0 |
| 164 | Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 714447 | 5.7 | 0 |
| 163 | Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic $\beta$ cells in diabetic db/db mice. <i>Scientific Reports</i> , <b>2021</b> , 11, 16120   | 4.9 | 1 |
| 162 | Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas: case report. <i>BMC Endocrine Disorders</i> , <b>2021</b> , 21, 164   | 3.3 | 0 |

|     |  |     |    |
|-----|--|-----|----|
| 161 | Notable Underlying Mechanism for Pancreatic $\beta$ Cell Dysfunction and Atherosclerosis: Pleiotropic Roles of Incretin and Insulin Signaling. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  | 6.3 | 2  |
| 160 | Association Between Severity of Diabetic Neuropathy and Success in Weight Loss During Hospitalization Among Japanese Patients with Type 2 Diabetes: A Retrospective Observational Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 1669-1676    | 3.4 |    |
| 159 | Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 906-916                                       | 3.9 | 4  |
| 158 | Insulin allergy brought out 8 years after starting insulin therapy in a subject with type 1 diabetes mellitus. <i>Acta Diabetologica</i> , <b>2020</b> , 57, 1025-1026   | 3.9 | 3  |
| 157 | Association of increased hepatic insulin clearance and change in serum triglycerides or $\beta$ -hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 947-956                             | 6.7 | 6  |
| 156 | Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 1612-1622                    | 3.9 | 21 |
| 155 | Effect of Combination Therapy of Canagliflozin Added to Tenzinogliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study. <i>Journal of Diabetes Research</i> , <b>2020</b> , 2020, 4861681  | 3.9 | 2  |
| 154 | Basal insulin secretion capacity predicts the initial response and maximum levels of $\beta$ -hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 222-230 | 6.7 | 3  |
| 153 | Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus: An uncontrolled, open-label extension of a phase III study. <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 662-671                        | 3.9 | 4  |
| 152 | Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 211-221   | 4.1 | 9  |
| 151 | Impact of physical activity and sedentary time on glycosylated hemoglobin levels and body composition: Cross-sectional study using outpatient clinical data of Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 633-639                    | 3.9 | 2  |
| 150 | Basedow's disease with associated features of Hashimoto's thyroiditis based on histopathological findings. <i>BMC Endocrine Disorders</i> , <b>2020</b> , 20, 120  | 3.3 | 2  |
| 149 | Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study). <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 405-416  | 3.9 | 1  |
| 148 | Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase III study. <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 373-381  | 3.9 | 4  |
| 147 | Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 132-141   | 3.9 | 4  |
| 146 | Severe hypertriglyceridemia in a subject with disturbed life style and poor glycemic control without recurrence of acute pancreatitis: a case report. <i>BMC Endocrine Disorders</i> , <b>2019</b> , 19, 92  | 3.3 | 2  |
| 145 | Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 2021-2040.e11  | 3.5 | 11 |
| 144 | Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2284-2293  | 6.7 | 20 |

|     |  |      |    |
|-----|--|------|----|
| 143 | Vascular endothelial PDK1 plays a pivotal role in the maintenance of pancreatic beta cell mass and function in adult male mice. <i>Diabetologia</i> , <b>2019</b> , 62, 1225-1236  | 10.3 | 6  |
| 142 | Long-term safety and efficacy of the sodium-glucose cotransporter2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 1510-1521 | 3.9  | 4  |
| 141 | Idiopathic and isolated adrenocorticotrophic hormone deficiency presenting as continuous epigastric discomfort without symptoms of hypoglycemia: a case report. <i>Journal of Medical Case Reports</i> , <b>2019</b> , 13, 113   | 1.2  |    |
| 140 | Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation. <i>Journal of Neurogastroenterology and Motility</i> , <b>2019</b> , 25, 332-333  | 4.4  |    |
| 139 | Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1445-1454  | 6.7  | 10 |
| 138 | Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1715-1724   | 6.7  | 3  |
| 137 | Eicosapentaenoic acid/arachidonic acid ratio and weight loss during hospitalization for glycemic control among overweight Japanese patients with type 2 diabetes: a retrospective observational study. <i>Lipids in Health and Disease</i> , <b>2019</b> , 18, 36  | 4.4  | 0  |
| 136 | Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 136-145   | 6.7  | 9  |
| 135 | Verification of Kumamoto Declaration 2013 and Glycemic Targets for Elderly Patients with Diabetes in Japan for prevention of diabetic complications: A retrospective longitudinal study using outpatient clinical data. <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 290-301   | 3.9  | 3  |
| 134 | Dramatic Improvement of Glycemic Control by Promptly Starting Steroid Therapy at an Early Stage of Autoimmune Pancreatitis in a Subject with Type 2 Diabetes. <i>Internal Medicine</i> , <b>2019</b> , 58, 3427-3431   | 1.1  | 1  |
| 133 | Comparison of HbA1c levels and body mass index for prevention of diabetic kidney disease: A retrospective longitudinal study using outpatient clinical data in Japanese patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 155, 107807   | 7.4  | 6  |
| 132 | Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2674-2683                   | 6.7  | 10 |
| 131 | Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 3647-3660   | 5.6  | 12 |
| 130 | Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , <b>2019</b> , 157, 898-899   | 13.3 | 1  |
| 129 | Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. <i>Drug Safety</i> , <b>2019</b> , 42, 1311-1327  | 5.1  | 9  |
| 128 | Alteration of ACTH and Cortisol Levels After Estradiol Valerate Treatment in a Male Subject With Gender Dysphoria: A Case Report. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 751  | 5.7  | 2  |
| 127 | Safety and efficacy of tofogliflozin in Japanese patients with type2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 1272-1283   | 3.9  | 7  |
| 126 | Association of the Glycemic Fluctuation as well as Glycemic Control with the Pancreatic βcell Function in Japanese Subjects with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , <b>2019</b> , 58, 167-173  | 1.1  | 5  |

|     |  |     |    |
|-----|--|-----|----|
| 125 | Acute exacerbation of chronic osteomyelitis triggered by aggravation of type 2 diabetes mellitus: a case report. <i>Journal of Medical Case Reports</i> , <b>2019</b> , 13, 7  | 1.2 | 1  |
| 124 | Suppression of free fatty acid receptor 1 expression in pancreatic $\beta$ cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1. <i>Endocrine Journal</i> , <b>2019</b> , 66, 43-50  | 2.9 | 2  |
| 123 | Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2019</b> , 7, 115-134  | 7.9 | 39 |
| 122 | Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study. <i>Heart and Vessels</i> , <b>2019</b> , 34, 375-384   | 2.1 | 2  |
| 121 | Effect of mild exercise on glycemic and bodyweight control in Japanese type 2 diabetes patients: A retrospective analysis. <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 104-107  | 3.9 | 1  |
| 120 | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase-4 inhibitor vildagliptin. <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 182-185   | 3.9 | 8  |
| 119 | Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism. <i>Scientific Reports</i> , <b>2018</b> , 8, 3725  | 4.9 | 13 |
| 118 | Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 1119-1127  | 3.9 | 2  |
| 117 | Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 840-849   | 3.9 | 5  |
| 116 | Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1202-1212  | 6.7 | 49 |
| 115 | Aggravation of type 2 diabetes mellitus triggered by acute exacerbation of chronic thyroiditis (Hashimoto's disease). <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 226-227  | 3.9 |    |
| 114 | Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1176-1185                          | 6.7 | 19 |
| 113 | Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2018</b> , 1, e00015   | 2.7 | 7  |
| 112 | Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 862-869  | 3.9 | 9  |
| 111 | Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 831-839 | 3.9 | 3  |
| 110 | Non-clostridial gas gangrene in a patient with poorly controlled type 2 diabetes mellitus on hemodialysis. <i>Acta Diabetologica</i> , <b>2018</b> , 55, 99-101  | 3.9 | 2  |
| 109 | Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 354-359  | 3.9 | 8  |
| 108 | There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1569-1580   | 3.6 | 6  |

|     |   |      |    |
|-----|---|------|----|
| 107 | Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 603-613   | 18.8 | 20 |
| 106 | Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity. <i>Scientific Reports</i> , <b>2018</b> , 8, 10644  | 4.9  | 12 |
| 105 | Fulminant Type 1 Diabetes Mellitus Complicated with a Life-threatening Electrolyte Abnormality and Abnormal Electrocardiogram Findings. <i>Internal Medicine</i> , <b>2018</b> , 57, 2685-2688  | 1.1  |    |
| 104 | Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2490-2493   | 6.7  | 6  |
| 103 | Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic $\beta$ cells in db/db mice: The earlier and longer, the better. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2442-2457   | 6.7  | 20 |
| 102 | Onset of type 1 diabetes mellitus and heparin-induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 1381-1382   | 3.9  | 0  |
| 101 | Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 1378-1380   | 3.9  | 1  |
| 100 | Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1061-1065  | 6.7  | 12 |
| 99  | Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 875-881  | 3.9  | 9  |
| 98  | Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 812-820  | 6.7  | 9  |
| 97  | Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study. <i>Journal of Diabetes Research</i> , <b>2018</b> , 2018, 9435401                               | 3.9  | 1  |
| 96  | Saibokuto as a Possible Therapy for Type B Insulin Resistance Syndrome: The Disappearance of Anti-insulin Receptor Antibody and a Marked Amelioration of Glycemic Control by Saibokuto Treatment. <i>Internal Medicine</i> , <b>2018</b> , 57, 2359-2363  | 1.1  | 2  |
| 95  | A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes. <i>PLoS ONE</i> , <b>2018</b> , 13, e0208654   | 3.7  | 12 |
| 94  | A rare case of large pyosalpinx in an elderly patient with well-controlled type 2 diabetes mellitus: a case report. <i>Journal of Medical Case Reports</i> , <b>2018</b> , 12, 286  | 1.2  | 1  |
| 93  | Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 331-335   | 3.2  | 7  |
| 92  | Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis. <i>Internal Medicine</i> , <b>2018</b> , 57, 1381-1389  | 1.1  | 2  |
| 91  | This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin unsubstantiated". <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2041-2042 | 6.7  |    |
| 90  | Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport. <i>Journal of Diabetes Investigation</i> , <b>2018</b> , 9, 1261-1269   | 3.9  | 10 |

|    |   |      |     |
|----|---|------|-----|
| 89 | Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , <b>2018</b> , 2018, 6470137  | 3.9  | 18  |
| 88 | A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion. <i>Journal of Molecular Medicine</i> , <b>2017</b> , 95, 361-368   | 5.5  | 18  |
| 87 | Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study). <i>Journal of Diabetes Investigation</i> , <b>2017</b> , 8, 766-775   | 3.9  | 26  |
| 86 | Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data. <i>Diabetes Therapy</i> , <b>2017</b> , 8, 189-195   | 3.6  | 5   |
| 85 | Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 463-467  | 6.7  | 9   |
| 84 | Bilateral lower limb edema induced by rapid improvement of glycemic control with insulin therapy in a subject with poorly controlled type 2 diabetes. <i>Acta Diabetologica</i> , <b>2017</b> , 54, 611-613   | 3.9  | 4   |
| 83 | Advanced breast cancer in a relatively young man with severe obesity and type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , <b>2017</b> , 8, 395-396  | 3.9  | 7   |
| 82 | Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1397-1407 | 6.7  | 29  |
| 81 | Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. <i>Advances in Therapy</i> , <b>2017</b> , 34, 436-451   | 4.1  | 76  |
| 80 | Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 951-964   | 18.1 | 141 |
| 79 | Werner Syndrome and Diabetes Mellitus Accompanied by Adrenal Cortex Cancer. <i>Internal Medicine</i> , <b>2017</b> , 56, 1987-1992  | 1.1  | 3   |
| 78 | Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME. <i>Circulation Journal</i> , <b>2017</b> , 81, 227-234   | 2.9  | 80  |
| 77 | Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , <b>2017</b> , 2017, 5856475  | 3.9  | 2   |
| 76 | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke - Reply. <i>Circulation Journal</i> , <b>2017</b> , 81, 899-902  | 2.9  | 1   |
| 75 | Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1313-1322  | 4.1  | 8   |
| 74 | Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor. <i>Diabetes and Vascular Disease Research</i> , <b>2017</b> , 14, 540-548                                       | 3.3  | 11  |
| 73 | Insulin degludec in a simple or stepwise titration algorithm in a Japanese population of patients with type 2 diabetes: a randomized, 26-week, treat-to-target trial. <i>Diabetology International</i> , <b>2017</b> , 8, 87-94   | 2.3  | 3   |
| 72 | Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic $\beta$ cell function and reduction of insulin resistance. <i>Journal of Diabetes</i> , <b>2017</b> , 9, 219-225   | 3.8  | 33  |

|    |   |      |      |
|----|---|------|------|
| 71 | Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice. <i>Journal of Diabetes Investigation</i> , <b>2017</b> , 8, 155-160   | 3.9  | 20   |
| 70 | Temporal lobe epilepsy associated with GAD autoimmunity. <i>Acta Diabetologica</i> , <b>2017</b> , 54, 321-323  | 3.9  |      |
| 69 | Clinical course of pituitary function and image in IgG4-related hypophysitis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , <b>2017</b> , 2017,  | 1.4  | 7    |
| 68 | Hypoglycemic Coma Induced by the Use of Succinic Acid Cibenzoline in Frail Late-stage Elderly Subjects. <i>Internal Medicine</i> , <b>2017</b> , 56, 1527-1529  | 1.1  | 1    |
| 67 | Optimal cut-off value of alanine aminotransferase level to precisely estimate the presence of fatty liver in patients with poorly controlled type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 645-6   | 3.9  | 2    |
| 66 | Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 674-6  | 3.9  | 6    |
| 65 | Hamman-Rich syndrome triggered by the onset of type 1 diabetes mellitus accompanied by diabetic ketoacidosis. <i>Acta Diabetologica</i> , <b>2016</b> , 53, 1067-1068   | 3.9  | 2    |
| 64 | Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. <i>Nature Communications</i> , <b>2016</b> , 7, 10531   | 17.4 | 99   |
| 63 | Ice Cube Tray-Shaped Insulin Lipoatrophy Throughout the Abdomen in a Subject With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, e4-5  | 14.6 | 20   |
| 62 | Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 843-862.e9 | 3.5  | 31   |
| 61 | Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic $\beta$ cells in obese type 2 diabetic db/db mice. <i>Biochemical and Biophysical Research Communications</i> , <b>2016</b> , 470, 772-782   | 3.4  | 36   |
| 60 | Replication Study in a Japanese Population of Six Susceptibility Loci for Type 2 Diabetes Originally Identified by a Transethnic Meta-Analysis of Genome-Wide Association Studies. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154093   | 17.7 | 1093 |
| 59 | The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002051   | 11.6 | 48   |
| 58 | Dramatic mitigation of bone pain after phosphorus replacement therapy in a subject with FGF23-related hypophosphatemic osteomalacia. <i>SpringerPlus</i> , <b>2016</b> , 5, 1904  |      | 1    |
| 57 | Human serum albumin: Possible cause of insulin autoimmune syndrome. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 919-920   | 3.9  | 4    |
| 56 | Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 66-88.e20                                      | 3.5  | 44   |
| 55 | Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic $\beta$ cell function in subjects with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1201-3                             | 3.2  | 5    |
| 54 | Association of GA/HbA1c ratio and cognitive impairment in subjects with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1452-1455  | 3.2  | 16   |

|    |  |      |     |
|----|--|------|-----|
| 53 | Influence of thyroid volume on the effect of methimazole in Japanese subjects with mild Graves disease. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 36, e31-e32   | 3.9  | 1   |
| 52 | Strawberry milk-like blood in a subject with diabetic lipemia: dramatic change to transparent color after insulin therapy. <i>SpringerPlus</i> , <b>2016</b> , 5, 1499   |      | 2   |
| 51 | Case of disseminated pyomyositis in poorly controlled type 2 diabetes mellitus with diabetic ketoacidosis. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 637-640   | 3.9  | 3   |
| 50 | Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 565-73 <sup>3.9</sup>   |      | 43  |
| 49 | Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 718-26 | 3.9  | 12  |
| 48 | Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 711-7         | 3.9  | 10  |
| 47 | Appropriate therapy for type 2 diabetes mellitus in view of pancreatic $\beta$ cell glucose toxicity: "the earlier, the better". <i>Journal of Diabetes</i> , <b>2016</b> , 8, 183-9   | 3.8  | 16  |
| 46 | Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis. <i>Journal of Diabetes Investigation</i> , <b>2016</b> , 7, 755-63  | 3.9  | 8   |
| 45 | Protective effects of pioglitazone and/or liraglutide on pancreatic $\beta$ cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes. <i>Molecular and Cellular Endocrinology</i> , <b>2015</b> , 400, 78-89  | 4.4  | 34  |
| 44 | Combination of DPP-4 inhibitor and PPAR $\gamma$ agonist exerts protective effects on pancreatic $\beta$ cells in diabetic db/db mice through the augmentation of IRS-2 expression. <i>Molecular and Cellular Endocrinology</i> , <b>2015</b> , 413, 49-60   | 4.4  | 20  |
| 43 | Replication study of the association of rs7578597 in THADA, rs10886471 in GRK5, and rs7403531 in RASGRP1 with susceptibility to type 2 diabetes among a Japanese population. <i>Diabetology International</i> , <b>2015</b> , 6, 306-312   | 2.3  | 1   |
| 42 | A case of hypothalamic hypopituitarism accompanied by recurrent severe hypoglycemia. <i>SpringerPlus</i> , <b>2015</b> , 4, 173  |      | 3   |
| 41 | First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2539-47   | 4    | 32  |
| 40 | Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , <b>2015</b> , 6, 443-53  | 3.9  | 39  |
| 39 | Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 191-7  | 18.1 | 65  |
| 38 | Dietary restriction preserves the mass and function of pancreatic $\beta$ cells via cell kinetic regulation and suppression of oxidative/ER stress in diabetic mice. <i>Journal of Nutritional Biochemistry</i> , <b>2015</b> , 26, 219-26   | 6.3  | 17  |
| 37 | GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4714-28  | 15.9 | 106 |
| 36 | Replication Study in a Japanese Population to Evaluate the Association between 10 SNP Loci, Identified in European Genome-Wide Association Studies, and Type 2 Diabetes. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126363 <sup>3.7</sup> <sup>9</sup>  |      |     |

|    |  |      |     |
|----|--|------|-----|
| 35 | Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. <i>Diabetes Therapy</i> , <b>2014</b> , 5, 97-111  | 3.6  | 7   |
| 34 | Are both protein kinase A- and protein kinase C-dependent pathways involved in glucagon-like peptide-1 action on pancreatic insulin secretion?. <i>Journal of Diabetes Investigation</i> , <b>2014</b> , 5, 347-8  | 3.9  | 2   |
| 33 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. <i>Cardiovascular Diabetology</i> , <b>2014</b> , 13, 65                               | 8.7  | 135 |
| 32 | SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 125-32  | 18.1 | 42  |
| 31 | Efficacy of voglibose in type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1181-90   | 4    | 34  |
| 30 | Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 2121-30   | 4    | 28  |
| 29 | Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 749-66 | 4    | 65  |
| 28 | Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. <i>Diabetes Therapy</i> , <b>2014</b> , 5, 415-33  | 3.6  | 53  |
| 27 | Fasiglifam as a new potential treatment option for patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2591-600  | 4    | 15  |
| 26 | Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , <b>2013</b> , 101, 35-44  | 7.4  | 9   |
| 25 | Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 245-50   | 14.6 | 93  |
| 24 | Predictive values of serum insulin kinetics for reversion of impaired glucose tolerance to normal glucose tolerance and the effects of voglibose treatment: a retrospective post hoc analysis of a Japanese phase III study. <i>Diabetology International</i> , <b>2012</b> , 3, 209-216   | 2.3  | 2   |
| 23 | Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. <i>Combination Products in Therapy</i> , <b>2012</b> , 2, 1   |      | 2   |
| 22 | Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , <b>2012</b> , 3, 302-8  | 3.9  | 14  |
| 21 | Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. <i>Journal of Diabetes Investigation</i> , <b>2012</b> , 3, 517-25  | 3.9  | 27  |
| 20 | The once-daily human glucagon-like peptide-1 analog, liraglutide, improves $\beta$ cell function in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2012</b> , 3, 388-95   | 3.9  | 11  |
| 19 | The PREDICTIVETM Study: a multinational, prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetes—data from the Japan cohort. <i>Diabetology International</i> , <b>2012</b> , 3, 11-20   | 2.3  | 1   |
| 18 | Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. <i>Current Medical Research and Opinion</i> , <b>2011</b> , 27 Suppl 3, 21-9  | 2.5  | 50  |

|    |  |     |    |
|----|--|-----|----|
| 17 | Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. <i>Current Medical Research and Opinion</i> , <b>2011</b> , 27, 1781-92   | 2.5 | 67 |
| 16 | Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. <i>Journal of Diabetes Investigation</i> , <b>2011</b> , 2, 280-6                         | 3.9 | 24 |
| 15 | Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2011</b> , 2, 441-7  | 3.9 | 33 |
| 14 | Thiazolidinediones and bone fractures. <i>Journal of Diabetes Investigation</i> , <b>2011</b> , 2, 354-5   | 3.9 | 3  |
| 13 | Safety and efficacy of switching thrice-daily treatment with NovoRapid <sup>®</sup> 70Mix (BIAsp70) to BIAsp70 before breakfast and lunch and NovoRapid <sup>®</sup> 30Mix (BIAsp30) before dinner in patients with type 2 diabetes: subgroup analysis of a phase III trial. <i>Diabetology International</i> , <b>2011</b> , 2, 183-189 | 2.3 | 1  |
| 12 | Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , <b>2011</b> , 27 Suppl 3, 73-84   | 2.5 | 1  |
| 11 | 28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , <b>2010</b> , 1, 103-10   | 3.9 | 4  |
| 10 | Adrenal Insufficiency Unmasked by Anti-HIV Therapy in a Patient with Acquired Immunodeficiency Syndrome.. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2010</b> , 99, 1061-1063  | 0   |    |
| 9  | Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1111-9  | 2.5 | 22 |
| 8  | Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 2925-32   | 2.5 | 18 |
| 7  | Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. <i>Endocrine Journal</i> , <b>2009</b> , 56, 657-64  | 2.9 | 9  |
| 6  | Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. <i>Endocrine Journal</i> , <b>2009</b> , 56, 739-46  | 2.9 | 13 |
| 5  | Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. <i>Journal of Pharmacological Sciences</i> , <b>2008</b> , 108, 274-9  | 3.7 | 21 |
| 4  | Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus. <i>Journal of Human Genetics</i> , <b>2005</b> , 50, 283-292  | 4.3 | 63 |
| 3  | Retained capacity of glucose-mediated insulin secretion in patients with type 2 diabetes mellitus inversely correlates with the duration of diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2004</b> , 64, 221-34  | 3.4 | 3  |
| 2  | Familial hypoalphalipoproteinemia, type 2 diabetes mellitus and markedly advanced atherosclerosis who had ABCA1 exon 4 minus transcript in macrophages.. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2002</b> , 91, 2762-2764   | 0   | 4  |
| 1  | A pitfall in hemoglobin A1c measurement with high performance liquid chromatography method in the diagnosis of onset of fulminant type 1 diabetes mellitus. <i>Journal of Diabetes Investigation</i> ,   | 3.9 |    |